Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 4/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.48 |
| ▸ | RELA | Q04206 | 4/20 | 0.48 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14089803 | 0.87 | BTK (0.51) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL25225626 | 0.87 | BTK (0.51) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL25648879 | 0.87 | NFKB1 (0.49) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL25423563 | 0.87 | BTK (0.51) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL28572940 | 0.78 | NFKB1 (0.51) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL31454795 | 0.78 | NFKB1 (0.51) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL2134159 | 0.78 | NFKB1 (0.51) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL12951314 | 0.78 | NFKB1 (0.51) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL2134157 | 0.78 | NFKB1 (0.51) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL13334908 | 0.78 | NFKB1 (0.51) | NFKB1NFKB2RELABTKKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4634184-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING KINASES VIA UBIQUITIN PROTEOSOME PATHWAY | Crossfire Oncology Holding B.V. (NL) | 2025-10-22 | — | — | EP | disclosed |
| US-20250074911-A1 | MACROCYCLIC BTK INHIBITORS | CROSSFIRE ONCOLOGY HOLDING B.V. (NL) | 2025-03-06 | — | — | US | disclosed |
| WO-2024256568-A1 | SALT AND CRYSTAL FORMS OF A MACROCYCLIC BTK INHIBITOR | CROSSFIRE ONCOLOGY HOLDING B.V. (NL) | 2024-12-19 | — | — | WO | disclosed |
| WO-2024245578-A1 | THERAPEUTIC COMBINATIONS OF AN IRREVERSIBLE BTK INHIBITOR AND A MACROCYCLIC REVERSIBLE BTK INHIBITOR | NETHERLANDS TRANSLATIONAL RESEARCH CENTER HOLDING B.V. (NL) | 2024-12-05 | — | — | WO | disclosed |
| WO-2024246287-A1 | MEDICAL USE OF A MACROCYCLIC REVERSIBLE BTK INHIBITOR | CROSSFIRE ONCOLOGY HOLDING B.V. (NL) | 2024-12-05 | — | — | WO | disclosed |
| EP-4448521-A1 | REVERSIBLE MACROCYCLIC KINASE INHIBITORS | Crossfire Oncology Holding B.V. (NL) | 2024-10-23 | — | — | EP | disclosed |
| EP-4448523-A1 | MACROCYCLIC BTK INHIBITORS | Crossfire Oncology Holding B.V. (NL) | 2024-10-23 | — | — | EP | disclosed |
| CN-118696041-A | Macrocyclic BTK inhibitors | 克罗斯费尔肿瘤学控股有限公司 | 2024-09-24 | — | — | CN | disclosed |
| WO-2024126617-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING KINASES VIA UBIQUITIN PROTEOSOME PATHWAY | CROSSFIRE ONCOLOGY HOLDING B.V. (NL) | 2024-06-20 | — | — | WO | disclosed |
| WO-2023110970-A1 | MACROCYCLIC BTK INHIBITORS | NETHERLANDS TRANSLATIONAL RESEARCH CENTER HOLDING B.V (NL) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023110936-A1 | REVERSIBLE MACROCYCLIC KINASE INHIBITORS | NETHERLANDS TRANSLATIONAL RESEARCH CENTER HOLDING B.V (NL) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074911-A1 | MACROCYCLIC BTK INHIBITORS | BTK, LYN, LCK | NFKB1 996/4885NFKB2 1010/4885RELA 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.